Active Ingredient History
Mirtazapine, originally known as ORG 3770, was first synthesized by the Department of Medicinal Chemistry of NV Organon in the Netherlands (Kaspersen et al. 1989). First approved for use in major depression in the Netherlands in 1994, mirtazapine was introduced in the United States in 1996. The antidepressant mirtazapine has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors. It enhances, therefore, the release of norepinephrine and 5-HT1A-mediated serotonergic transmission. This dual mode of action may conceivably be responsible for mirtazapine's rapid onset of action. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcohol Drinking (Phase 2)
Alcoholism (Phase 2)
Alzheimer Disease (Phase 3)
Amphetamine-Related Disorders (Phase 3)
Anorexia (Phase 3)
Anxiety (Phase 4)
Anxiety Disorders (Phase 3)
Asthma (Phase 4)
Autism Spectrum Disorder (Phase 3)
Bipolar Disorder (Phase 4)
Breast Neoplasms (Phase 3)
Cachexia (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Cardiovascular Abnormalities (Phase 1)
Cocaine-Related Disorders (Phase 2)
Counseling (Phase 1/Phase 2)
Dementia (Phase 3)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 3)
Disorders of Excessive Somnolence (Phase 2)
Drug Interactions (Phase 1)
Dyspepsia (Phase 4)
Dyssomnias (Phase 3)
Enteral Nutrition (Phase 4)
Fibromyalgia (Phase 2)
Glioma (Early Phase 1)
Headache (Phase 4)
Head and Neck Neoplasms (Phase 4)
Healthy Volunteers (Phase 1)
Heroin Dependence (Phase 3)
HIV Infections (Phase 2)
Hyperemesis Gravidarum (Phase 2)
Lung Neoplasms (Phase 4)
Menopause (Phase 3)
Mental Disorders (Phase 4)
Methamphetamine (Phase 1)
Mood Disorders (Phase 4)
Nausea (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 4)
Pain (Phase 4)
Pancreatic Neoplasms (Phase 4)
Postmenopause (Phase 3)
Postoperative Nausea and Vomiting (Phase 4)
Pregnancy (Phase 1/Phase 2)
Pregnancy Complications (Phase 2)
Psychophysiologic Disorders (Phase 3)
Quality of Life (Phase 4)
Schizophrenia (Phase 4)
Shivering (Phase 4)
Sleep (Phase 3)
Sleep Apnea, Obstructive (Phase 1)
Sleep Apnea Syndromes (Phase 2)
Sleep Disorders, Intrinsic (Phase 3)
Sleep Wake Disorders (Phase 3)
Spinal Cord Injuries (Phase 2)
Stress Disorders, Post-Traumatic (Phase 4)
Substance-Related Disorders (Phase 2)
Substance Withdrawal Syndrome (Phase 2)
Suicide, Attempted (Phase 2/Phase 3)
Vasomotor System (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
